Navigation Links
World Health Organization thanks CBM For their outstanding work
Date:10/10/2007

TORONTO, Oct. 10 /PRNewswire/ - CBM President Professor Allen Foster met with the Director-General Dr Margaret Chan, for the World Health Organizations global initiative to eliminate avoidable blindness "Vision 2020: The Right to Sight" on the eve of World Sight Day 2007 at WHO Headquarters Geneva.

Dr. Chan thanked CBM for their longstanding 20 year partnership and support, both financially and with technical personnel, for the prevention of blindness, deafness and for other disability related programmes in the developing World.

World Sight Day 2007 will be celebrated on Thursday 11th October to focus global attention on blindness and vision impairment for Children.

"Early intervention is key to ensuring that children with eye problems have the best possible outcomes in the developing countries," says Prof. Foster. "Almost 50 percent of the world's 1.4 million children living without sight are needlessly blind, from avoidable causes. This is a major public health priority that needs to be addressed."

Every minute, a child goes blind - in the developing world, a child has a 60% chance of dying within one year of going blind. Over 1 million children in the developing world under the age of 15 are now blind.

CBM is a founding member of VISION 2020: the Right to Sight which is a global initiative of the World Health Organization (WHO) and the International Agency for the Prevention of Blindness (IAPB). We are working together to eliminate avoidable blindness worldwide by the year 2020, in order to give everyone in the world the Right to Sight.

CBM currently supports 1,011 disability-focused projects in 112 countries in Africa, Asia, Latin America and Eastern Europe. CBM has performed 8 million cataract surgeries worldwide.

CBM is an expert at helping people with disabilities throughout the developing world.

/NOTE TO PHOTO EDITORS: A photo accompanying this release is available on

the CNW Photo Network and arch
'/>"/>

SOURCE CBMI Canada
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Oracle Corp. to help build worlds first "Digital Hospital"
2. The World Bank funds private Hospital in India
3. Exclusive breast-feeding advised for six months in infants recommends World Health Organization
4. Half of worlds children are passive smokers - damning disclosure from WHO
5. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
6. Televisions ruling babys world!
7. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
8. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
9. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
10. World SARS-free within weeks
11. Worlds oldest turns 116 in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8Steaz Launches Organic Zero Calorie Sparkling Line 59893 1Steaz Launches Organic Zero Calorie Sparkling Line 59893 2Henry Schein to Webcast Third Quarter 2009 Conference Call Wednesday November 4 at 10 A M EST 59891 1Henry Schein to Webcast Third Quarter 2009 Conference Call Wednesday November 4 at 10 A M EST 59891 2Bioidentical Hormones a True Prevention for Breast Cancer 59889 1Bioidentical Hormones a True Prevention for Breast Cancer 59889 2